Moreover, XJ Meng et al. evaluated brain metastatic lesions in advanced NSCLC patients after EGFR-TKIs resistance and found that immunotherapy + chemotherapy had effective intracranial efficacy and clearly prolonged patients’ PFS compared with chemotherapy [37]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.